Holen Sie sich die Stockscreener-App
7.51
1.62%
0.12
Handel nachbörslich:
7.52
0.010
+0.13%
Schlusskurs vom Vortag:
$7.39
Offen:
$7.31
24-Stunden-Volumen:
231.77K
Relative Volume:
0.74
Marktkapitalisierung:
$489.26M
Einnahmen:
$36.90M
Nettoeinkommen (Verlust:
$-166.28M
KGV:
-2.2827
EPS:
-3.29
Netto-Cashflow:
$-203.53M
1W Leistung:
+6.22%
1M Leistung:
-17.29%
6M Leistung:
-71.87%
1J Leistung:
-67.97%
1-Tages-Spanne:
$7.31
$7.80
1-Wochen-Bereich:
$6.97
$8.00
52-Wochen-Spanne:
$6.10
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Firmenname
Bicycle Therapeutics Plc Adr
Sektor
Branche
Telefon
011441223261503
Adresse
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Vergleichen Sie BCYC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
7.51 | 489.26M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Equal-Weight |
| 2024-09-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-07 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | Eingeleitet | Cowen | Outperform |
| 2022-07-28 | Eingeleitet | Barclays | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-04-13 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-02-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-09 | Eingeleitet | Needham | Buy |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Buy |
| 2021-04-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-09-11 | Hochstufung | Goldman | Neutral → Buy |
| 2019-06-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-17 | Eingeleitet | Goldman | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
| 2019-06-17 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock hits 52-week low at $11.14 By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa
Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bayer Reports Positive Safety Data on Parkinson's Disease Drug - Yahoo Finance
Finanzdaten der Bicycle Therapeutics Plc Adr-Aktie (BCYC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):